Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-002785-20-DE (EUCTR)	19/09/2011	11/08/2011	Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis	Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis - EVIDIMS	Multiple Sclerosis and Clinical isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Vigantol ® Öl 20.000 I.E./ml Product Name: Vigantol ® Öl 20.000 I.E./ml Product Code: Vigantol ® Öl 20.000 I.E./ml INN or Proposed INN: COLECALCIFEROL Trade Name: Dekristol®-Tablette 1 (400 IE) Product Name: Dekristol® 400-Tabletten Product Code: Dekristol® 400-Tabletten INN or Proposed INN: COLECALCIFEROL Other descriptive name: 25OH-Vitamin D	Charité - Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Germany
2	EUCTR2007-001958-99-FI (EUCTR)	18/12/2007	07/12/2007	Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS	Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS	Patients with relapsing remitting MS according to the revised Mc Donald's criteria who meet all criteria for inclusion and none criteria of exclusion. MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Trade Name: Dekristol 20000 IE Product Name: Dekristol INN or Proposed INN: INN COLECALCIFEROL Product Name: Placebo Dekristol SGC 20000	Merja Soilu Häninen	NULL	Not Recruiting			Female: yes Male: yes			Finland